Effectiveness and safety of warfarin in dialysis patients with atrial fibrillation: A meta-analysis of observational studies

Medicine (United States)

Volumn 94, Issue 50, 2015, Pages

  Liu, Gang ^a   Long, Ming ^a   Hu, Xun ^a   Hu, Cheng Heng ^a   Liao, Xin Xue ^a   Du, Zhi Min ^a   Dong, Yu Gang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CLINICAL EFFECTIVENESS; HEMODIALYSIS PATIENT; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; PATIENT SAFETY; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; COMPLICATION; KIDNEY FAILURE, CHRONIC; RENAL REPLACEMENT THERAPY; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; KIDNEY FAILURE, CHRONIC; OBSERVATIONAL STUDIES AS TOPIC; RENAL DIALYSIS; RISK ASSESSMENT; STROKE; WARFARIN;

EID: 84952652915     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002233     Document Type: Article

References (41)

1. Winkelmayer WC, Patrick AR, Liu J, et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol. 2011;22:349-357.
2. Wetmore JB, Mahnken JD, Rigler SK, et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int. 2012;81:469-476.
3. Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648-658.
4. Ikizler TA, Morrow JD, Roberts LJ, et al. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol. 2002;58:190-197.
5. Seliger SL, Gillen DL, Tirschwell D, et al. Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol. 2003;14:2623-2631.
6. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1:175-179.
7. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990;323:1505-1511.
8. Miller LM, Hopman WM, Garland JS, et al. Cardioprotective medication use indialysis patients. Can J Cardiol. 2006;22:755-760.
9. Clase CM, Holden RM, Sood MM, et al. Should patients with advanced chronic kidney disease and atrial fibrillation receive chronic anticoagulation? Nephrol Dial Transplant. 2012;27:3719-3724.
10. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15:2857-2867.
11. Shen JI, Montez-Rath ME, Lenihan CR, et al. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis. 2015;66:677-688.
12. Genovesi S, Rossi E, Gallieni M, et al. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. Nephrol Dial Transplant. 2015;30:491-498.
13. Chen CY, Lin TC, Yang Y. Use of warfarin and risk of stroke and mortality in chronic dialysis patients with atrial fibrillation in taiwan. Pharmacoepidemiol Drug Saf. 2014;23(Suppl 1):457-458.
14. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129:1196-1203.
15. Wakasugi M, Kazama JJ, Tokumoto A, et al. Association between warfarin use and incidence of ischemic stroke in Japanese dialysis patients with chronic sustained atrial fibrillation: a prospective cohort study. Clin Exp Nephrol. 2014;18:662-669.
16. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625-635.
17. Winkelmayer WC, Liu J, Setoguchi S, et al. Effectiveness and safety of warfarin initiation in older dialysis patients with incident atrial fibrillations. Clin J Am Soc Nephrol. 2011;6:2662-2668.
18. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation indialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010;77:1098-1106.
19. Chan KE, Lazarus JM, Thadhani R, et al. Warfarin use associates with increased risk for stroke indialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20:2223-2233.
20. Lai HM, Aronow WS, Kalen P, et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis. 2009;2:33-37.
21. Vázquez E, Sánchez-Perales C, García-Cortes MJ, et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? Int J Cardiol. 2003;87:135-139.
22. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
23. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed October 8, 2012.
24. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
25. Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation-friend or foe? Thromb Haemost. 2010;104:45-48.
26. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272.
27. Brimble KS, Ingram AJ, Eikelboom JW, et al. Anticoagulants in patients with atrial fibrillation and end-stage renal disease. Postgrad Med. 2012;124:17-25.
28. Zimmerman D, Sood MM, Rigatto C, et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant. 2012;27:3816-3822.
29. Li J, Wang L, Hu J, et al. Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: a systematic review and a meta-analysis. Nutr Metab Cardiovasc Dis. 2015;25:706-713.
30. Janssen MJ, Van Der Meulen J. The bleeding risk in chronic haemodialysis: preventive strategies in high-risk patients. Neth J Med. 1996;48:198-207.
31. Sreedhara R, Itagaki I, Lynn B, et al. Defective platelet aggregation in uremia is transiently worsened bydialysis. Am J Kidney Dis. 1995;25:555-563.
32. Nakano T, Kawamoto K, Kishino J, et al. Requirement of gammacarboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. Biochem J. 1997;323:387-392.
33. Schurgers LJ, Spronk HM, Skepper JN, et al. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost. 2007;5:2503-2511.
34. Seliger SL, Gillen DL, Longstreth WT Jr et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003;64:603-609.
35. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011;57:1339-1348.
36. Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164:880-884.
37. Manley HJ, Garvin CG, Drayer DK, et al. Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-forprofit dialysis provider. Nephrol Dial Transplant. 2004;19:1842-1848.
38. Atar I, Konas D, Acikel S, et al. Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol. 2006;106:47-51.
39. Suzuki S, Sagara K, Otsuka T, et al. Estimated glomerular filtration rate and proteinuria are associated with persistent form of atrial fibrillation: analysis in Japanese patients. J Cardiol. 2013;61:53-57.
40. Eiser AR. Warfarin, calciphylaxis, atrial fibrillation, and patients on dialysis: outlier subsets and practice guidelines. Am J Med. 2014;127:253-254.
41. Wilkieson TJ, Ingram AJ, Crowther MA, et al. Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clin J Am Soc Nephrol. 2011;6:1018-1024.